Drug Type Fluorophore-conjugated therapeutics |
Synonyms AVB-620D |
Target |
Mechanism MMPs inhibitors(Matrix metalloproteinase inhibitors), Diagnostic dye |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 3 | US | 13 Sep 2020 | |
Colorectal Cancer | Phase 2 | US | 09 Sep 2020 | |
Head and Neck Neoplasms | Phase 2 | US | 09 Sep 2020 | |
Breast Ductal Carcinoma | Phase 2 | US | 05 Jul 2017 | |
Lobular Carcinoma | Phase 2 | US | 05 Jul 2017 |
NCT03113825 (Biospace) Manual | Phase 2/3 | 32 | xbrtglweei(uvcaffvgyo) = no drug-related serious adverse events were reported bsorqwhxzt (ecmeltkqpo ) | Positive | 04 Aug 2020 |